FrancophonIA/ELRC3.0 huggingface dataset:
English: Very common side effects (may affect more than 1 in 10 people): - feeling depressed, irritability, trouble falling asleep or staying asleep, feeling anxious or nervous, difficulty concentrating, mood swings, - headache, dizziness, tired feeling, shaking chills, fever, flu-like symptoms, virus infection,
Estonian: Väga sagedased kõrvaltoimed (võivad tekkida rohkem kui ühel inimesel 10st): - masendus (depressioon), ärrituvus, uinumisraskused või unetus, ärevustunne või närvilisus,
English: PegIntron 50 micrograms powder and solvent for injection peginterferon alfa-2b
Estonian: PegIntron 50 mikrogrammi süstelahuse pulber ja lahusti alfa-2b-peginterferoon
English: Plasma HCV-RNA is measured with a research-based quantitative polymerase chain reaction assay by a central laboratory *Intent to treat population includes 7 patients for whom at least 12 weeks of prior therapy could not be confirmed.
Estonian: * Ravi sihtpopulatsioon hõlmab 7 patsienti, kellel ei suudetud tõestada, et nad said eelnevat vähemalt 12-nädalast ravi.
English: PegIntron 120 micrograms powder and solvent for injection peginterferon alfa-2b
Estonian: PegIntron 120 mikrogrammi süstelahuse pulber ja lahusti alfa-2b-peginterferoon
English: PegIntron 100 micrograms powder and solvent for solution for injection in pre-filled pen Each pre-filled pen contains 100 micrograms of peginterferon alfa-2b measured on a protein basis.
Estonian: PegIntron 100 mikrogrammi süstelahuse pulber ja lahusti pen-süstlis Iga pen-süstel sisaldab valgu baasil mõõdetuna 100 mikrogrammi alfa-2b-peginterferooni.
English: PegIntron 100 micrograms powder and solvent for injection peginterferon alfa-2b
Estonian: PegIntron 100 mikrogrammi süstelahuse pulber ja lahusti alfa-2b-peginterferoon
English: What PegIntron contains
Estonian: PegIntron lahusti Süstevesi
English: EU/1/00/131/008 (4 vials of powder, 4 ampoules of solvent) EU/1/00/131/009 (4 vials of powder, 4 ampoules of solvent, 4 injection syringes, 8 injection needles and 4 cleansing swabs)
Estonian: EU/1/00/131/006 (1 viaal pulbriga, 1 ampull lahustiga) EU/1/00/131/007 (1 viaal pulbriga, 1 ampull lahustiga, 1 süstal, 2 süstlanõela ja 1 puhastustampoon) EU/1/00/131/008 (4 viaali pulbriga, 4 ampulli lahustiga) EU/1/00/131/009 (4 viaali pulbriga, 4 ampulli lahustiga, 4 süstalt, 8 süstlanõela ja 4 puhastustampooni)
English: PegIntron 50 micrograms powder and solvent for solution for injection PegIntron 80 micrograms powder and solvent for solution for injection PegIntron 100 micrograms powder and solvent for solution for injection PegIntron 120 micrograms powder and solvent for solution for injection PegIntron 150 micrograms powder and solvent for solution for injection
Estonian: PegIntron 50 mikrogrammi süstelahuse pulber ja lahusti PegIntron 80 mikrogrammi süstelahuse pulber ja lahusti PegIntron 100 mikrogrammi süstelahuse pulber ja lahusti PegIntron 120 mikrogrammi süstelahuse pulber ja lahusti PegIntron 150 mikrogrammi süstelahuse pulber ja lahusti
English: EU/1/00/131/003 (4 vials of powder, 4 ampoules of solvent) EU/1/00/131/004 (4 vials of powder, 4 ampoules of solvent, 4 injection syringes, 8 injection needles and 4 cleansing swabs)
Estonian: EU/1/00/131/001 (1 viaal pulbriga, 1 ampull lahustiga) EU/1/00/131/002 (1 viaal pulbriga, 1 ampull lahustiga, 1 süstal, 2 süstlanõela ja 1 puhastustampoon) EU/1/00/131/003 (4 viaali pulbriga, 4 ampulli lahustiga) EU/1/00/131/004 (4 viaali pulbriga, 4 ampulli lahustiga, 4 süstalt, 8 süstlanõela ja 4 puhastustampooni)
English: PegIntron 120 micrograms powder and solvent for solution for injection in pre-filled pen peginterferon alfa-2b
Estonian: PegIntron 120 mikrogrammi süstelahuse pulber ja lahusti pen-süstlis alfa-2b-peginterferoon
English: PegIntron 80 micrograms powder and solvent for solution for injection in pre-filled pen peginterferon alfa-2b
Estonian: PegIntron 80 mikrogrammi süstelahuse pulber ja lahusti pen-süstlis alfa-2b-peginterferoon
English: PegIntron 1.5 micrograms/kg
Estonian: PegIntron 1,5 μg/kg
English: PegIntron 50 micrograms powder and solvent for solution for injection in pre-filled pen peginterferon alfa-2b
Estonian: PegIntron 50 mikrogrammi süstelahuse pulber ja lahusti pen-süstlis alfa-2b-peginterferoon
English: EU/1/00/131/018 (4 vials of powder, 4 ampoules of solvent) EU/1/00/131/019 (4 vials of powder, 4 ampoules of solvent, 4 injection syringes, 8 injection needles and 4 cleansing swabs)
Estonian: EU/1/00/131/016 (1 viaal pulbriga, 1 ampull lahustiga) EU/1/00/131/017 (1 viaal pulbriga, 1 ampull lahustiga, 1 süstal, 2 süstlanõela ja 1 puhastustampoon) EU/1/00/131/018 (4 viaali pulbriga, 4 ampulli lahustiga) EU/1/00/131/019 (4 viaali pulbriga, 4 ampulli lahustiga, 4 süstalt, 8 süstlanõela ja 4 puhastustampooni)
English: PegIntron 150 micrograms powder and solvent for solution for injection in pre-filled pen peginterferon alfa-2b
Estonian: PegIntron 150 mikrogrammi süstelahuse pulber ja lahusti pen-süstlis alfa-2b-peginterferoon
English: Careful co-administration of thioridazine with the product (PegIntron) is recommended.
Estonian: Soovitatav on PegIntroni ja tioridasiini koos manustada ettevaatusega.
English: PC:
Estonian: Harv:
English: Both active substances have been available in the European Union (EU) as separate preparations for a number of years.
Estonian: Mõlemat toimeainet on Euroopa Liidus aastaid turustatud eraldi ravimpreparaatidena.
English: What measures are being taken to ensure the safe and effective use of Omidria?
Estonian: Mis meetmed võetakse, et tagada Omidria ohutu ja efektiivne kasutamine?
English: A risk management plan has been developed to ensure that Omidria is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Omidria võimalikult ohutu kasutamine.
English: The full EPAR and risk management plan summary for Omidria can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst ja riskijuhtimiskava kokkuvõte Omidria kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Omidria on 28 July 2015.
Estonian: Euroopa Komisjon andis Omidria müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 28. juulil
English: Other information about Omidria
Estonian: Muu teave Omidria kohta
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Estonian: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom aktiveerib need, põhjustades nende lihaste kokkutõmbumist.
English: Although the effect of Omidria on pain was modest, it was considered clinically important.
Estonian: Kuigi Omidria toime valule oli tagasihoidlik, peeti seda kliiniliselt oluliseks.
English: This makes lens replacement surgery easier.
Estonian: See teeb silmaläätse vahetamise operatsiooni lihtsamaks.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that the benefits of Omidria are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Inimravimite komitee otsustas, et Omidria kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: In addition, 7% (29 out of 403) of patients receiving Omidria experienced moderate-to-severe pain compared with 14% (57 out of 403) of patients given placebo, and 25% (104 out of 403) were painfree in the early period following surgery, compared with 17% (69 out of 403) of patients receiving placebo.
Estonian: Lisaks tundis 7% (29 patsienti 403st) Omidriat saanud patsientidest mõõdukat kuni tugevat valu võrreldes 14%-ga (57 patsienti 403st) platseebot saanud patsientidest ning 25% (104 patsienti 403st) ei tundnud vahetult operatsioonijärgsel ajal valu võrreldes 17%-ga (69 patsienti 403st) platseebot saanud patsientidest.
English: What is Omidria and what is it used for?
Estonian: Mis on Omidria ja milleks seda kasutatakse?
English: Why is Omidria approved?
Estonian: Miks Omidria heaks kiideti?
English: The most common side effects with Omidria (which may affect up to 1 in 10 people) are eye pain, anterior chamber inflammation (inflammation of the fluid-filled space inside the eye between the iris and the cornea), conjunctival hyperaemia (redness of the membrane that lies over the white part of the eye), photophobia (increased sensitivity of the eyes to light), corneal oedema (swelling of the transparent layer in front of the eye that covers the pupil and iris) and inflammation.
Estonian: Omidria kõige sagedamad kõrvalnähud (võivad esineda kuni 1 patsiendil 10st) on silmavalu, eeskambri (vedelikuga täidetud kamber silmas viker- ja sarvkesta vahel) põletik, sidekesta hüpereemia (silmamuna eesmist osa katva kesta punetus), valguskartus (silmade suurenenud valgustundlikkus), sarvkesta (silma eesmises osas pupilli ja vikerkesta katva läbipaistva kihi) turse ja põletik.
English: In both studies, the main measures of effectiveness were the change in diameter of the pupil by the end of the surgery, and how much eye pain patients felt soon after surgery, as indicated by the patient using a standard pain scale from 1 to 100.
Estonian: Mõlemas uuringus olid efektiivsuse põhinäitajad pupilli diameetri muutumine operatsiooni lõpuks ja patsientide silmavalu tugevus varsti pärast operatsiooni, mida patsiendid mõõtsid standardsel valuskaalal 1-100.
English: What are the risks associated with Omidria?
Estonian: Mis riskid Omidriaga kaasnevad?
English: Omidria has been shown to be effective at maintaining pupil dilation and preventing pupil contraction during lens replacement surgery, which should help to make such surgery easier and safer.
Estonian: Tõestatud on Omidria efektiivsus pupillide laiendatuna hoidmisel ja nende ahenemise ärahoidmisel silmaläätse vahetamise operatsiooni ajal, mis peaks muutma sellise operatsiooni lihtsamaks ja ohutumaks.
English: The ophthalmologist may also prescribe eye drops commonly used before and after the surgery to help prevent eye infections and pain.
Estonian: Silmakirurg võib määrata ka silmatilgad, mida kasutatakse tavaliselt enne ja pärast operatsiooni silmainfektsioonide ja -valu ennetamiseks.
English: With regard to the safety of Omidria, the medicine was generally well tolerated.
Estonian: Ohutuse seisukohast taluti Omidriat üldiselt hästi.
English: It is not intended to provide practical advice on how to use Omidria.
Estonian: Hindamisaruandes ei anta Omidria kasutamise praktilisi nõuandeid.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Omidria, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Omidria omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: These side effects are typical following lens replacement surgery, and most were mild to moderate in severity and resolved spontaneously.
Estonian: Need kõrvalnähud on silmaläätse vahetamise operatsiooni järel tavalised ja enamik olid raskuselt kerged kuni mõõdukad ning kadusid iseenesest.
English: Omidria phenylephrine / ketorolac
Estonian: Omidria fenüülefriin/ketorolak
English: Omidria is a medicine used in adults during lens replacement surgery in the eye to keep the pupil dilated (widened) and prevent its contraction, and to reduce eye pain after surgery.
Estonian: Omidria on ravim, mida kasutatakse täiskasvanutel silmaläätse vahetamise operatsiooni ajal pupillide avamiseks (laiendamiseks) ja nende ahenemise vältimiseks ning silmavalu vähendamiseks operatsiooni järel.
English: When applied to the eye, ketorolac reduces the production of prostaglandins in the eye and thereby reduces the pain and inflammation caused by eye surgery.
Estonian: Silmas kasutamisel vähendab ketorolak prostaglandiinide teket silmas ning vähendab nii silmaoperatsiooni põhjustatavat valu ja põletikku.
English: For practical information about using Omidria, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Omidria kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: Both studies showed that the pupil remained dilated during surgery in patients given Omidria (+0.1 mm), while it contracted in those given placebo (-0.5 mm).
Estonian: Mõlemas uuringus tõendati, et pupill jäi operatsiooni ajal laiendatuks Omidriat saanud patsientidel (+0,1 mm), kuid ahenes platseebot saanud patsientidel (-0,5 mm).
English: Fewer than 1 in 10 of the patients given Omidria had a pupil diameter below 6 mm (which makes surgery more difficult), whereas about 4 patients in 10 experienced this after being given placebo.
Estonian: Vähem kui 1-l Omidriat saanud patsiendil 10st oli pupilli diameeter väiksem kui 6 mm (mis raskendab operatsiooni), platseebo korral aga ligi 4 patsiendil 10st.
English: This is a summary of the European public assessment report (EPAR) for Omidria.
Estonian: See on ravimi Omidria Euroopa avaliku hindamisaruande kokkuvõte.
English: Omidria must not be used in patients who have narrow-angle glaucoma, a serious condition of the eye in which the pressure inside the eye rises rapidly because fluid cannot drain out.
Estonian: Kinnise nurga glaukoom on raske silmahaigus, mille korral silmasisene rõhk tõuseb kiiresti, sest vedelik ei saa ära voolata.
English: For more information about treatment with Omidria, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Omidriaga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Omidria has been investigated in two main studies involving a total of 821 patients undergoing lens replacement surgery, in which it was compared with placebo (a dummy treatment).
Estonian: Omidriat uuriti kahes põhiuuringus, milles osales kokku 821 patsienti, kellele tehti silmaläätse vahetamise operatsioon.
English: The lens is the part of the eye that focuses light passing through the pupil and allows clear vision.
Estonian: Lääts on silmaosa, mis fookustab pupilli läbivat valgust, et nägemine oleks selge.
English: Ketorolac is a non-steroidal anti-inflammatory drug (NSAID).
Estonian: Ketorolak on mittesteroidne põletikuvastane ravim (NSAID).
English: For the full list of all side effects reported with Omidria, see the package leaflet.
Estonian: Omidria kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: How is Omidria used?
Estonian: Kuidas Omidriat kasutatakse?
English: What benefits of Omidria have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Omidria kasulikkus?
English: How does Omidria work?
Estonian: Kuidas Omidria toimib?
English: Phenylephrine is a ‘selective alpha-1 adrenergic receptor agonist', which attaches to and activates alpha-1 adrenergic receptors that are found on smooth muscle cells, causing these muscles to contract.
Estonian: Fenüülefriin on α1-adrenergilise retseptori selektiivne agonist, mis seondub silelihaste rakkude pinnal olevate α1-adrenergiliste retseptoritega ja
English: With respect to pain, patients treated with Omidria reported an average pain score of around 4, compared with around 9 for those given placebo.
Estonian: Omidriaga ravitud patsientide keskmine valuskoor oli ligikaudu 4 võrreldes ligikaudu 9-ga platseebot saanud patsientidel.
English: It can only be obtained with a prescription and must be given by a qualified ophthalmological surgeon (eye surgery specialist) experienced in lens replacement.
Estonian: Omidria on retseptiravim ja seda tohib kasutada üksnes kvalifitseeritud silmakirurg, kellel on silmaläätse vahetamise operatsioonide kogemus.
English: The recommended dose is 4 ml of Omidria diluted in 500 ml of irrigation solution, to be used during the surgery to replace the lens.
Estonian: Operatsiooni ajal läätse vahetamiseks kasutatav soovitatav annus on 4 ml Omidriat lahjendatuna 500 ml loputuslahuses.
English: Omidria is available as a concentrate that is made up into an irrigation solution (a solution used to rinse the inside of the eye during surgery).
Estonian: Omidriat turustatakse loputuslahuse kontsentraadina (operatsiooni ajal silma sisemuse loputamiseks kasutatav lahus).
English: This is a type of surgery in which a new lens is implanted into the eye.
Estonian: Sellise operatsiooni käigus siirdatakse silma uus lääts.
English: Omidria contains the active substances phenylephrine and ketorolac.
Estonian: Omidria sisaldab toimeainetena fenüülefriini ja ketorolakki.
English: The incidence of side effects with Omidria was similar to that reported in patients receiving placebo.
Estonian: Omidria kõrvalnähtude esinemissagedus oli sarnane platseebot saanud patsientide kõrvalnähtude esinemissagedusega.
English: When applied to the eye, phenylephrine makes the muscle of the iris contract (tighten) and allows the pupil to widen.
Estonian: Silmas kasutamisel surub fenüülefriin kokku vikerkesta laiendajalihase ja laiendab pupilli.
English: It works by blocking certain enzymes called cyclo-oxygenases, which produce prostaglandins, substances that are involved in pain and inflammation processes.
Estonian: Prostaglandiinid on ained, mis osalevad valu- ja põletikuprotsessis.
English: 21 February 2005
Estonian: 21. veebruar 2005
English: Therefore, AZILECT is not recommended for use under the age of 18.
Estonian: Seetõttu ei soovitata AZILECT'i kasutada alla 18-aastastel.
English: AZILECT may be taken with or without food.
Estonian: AZILECT'i võib võtta koos toiduga või ilma.
English: Its terminal half-life is 0.6-2 hours.
Estonian: Tema terminaalne poolväärtusaeg on 0,6…2 tundi.
English: Smoking could decrease the amount of AZILECT in the blood.
Estonian: Suitsetamine võib vähendada AZILECT'i hulka teie veres.
English: Other medicines and AZILECT
Estonian: Muud ravimid ja AZILECT
English: Tablet 30 tablets
Estonian: Tablett 30 tabletti
English: Take the AZILECT carton/ blister or bottle with you to show the doctor or pharmacist.
Estonian: Võtke AZILECT'i karp/blister või pudel kaasa, et seda arstile või apteekrile näidata.
English: Do not stop taking AZILECT without first talking to your doctor.
Estonian: Ärge lõpetage AZILECT'i võtmist ilma eelnevalt arstiga nõu pidamata.
English: Not known: frequency cannot be estimated from the available data - Elevated blood pressure - Excessive drowsiness - Sudden onset of sleep
Estonian: Teadmata: esinemissagedust ei saa hinnata olemasolevate andmete alusel - vererõhu tõus - ülemäärane unisus - ootamatu uinumine
English: What AZILECT is and what it is used for
Estonian: Mis ravim on AZILECT ja milleks seda kasutatakse
English: What AZILECT is and what it is used for What you need to know before you take AZILECT How to take AZILECT
Estonian: Mis ravim on AZILECT ja milleks seda kasutatakse Mida on vaja teada enne AZILECT'i võtmist Kuidas AZILECT'i võtta
English: AZILECT helps to increase and sustain levels of dopamine in the brain.
Estonian: AZILECT aitab suurendada ja säilitada dopamiini taset ajus.
English: The safety and efficacy of AZILECT in children and adolescents have not been established.
Estonian: AZILECT'i ohutus ja efektiivsus lastel ja noorukitel ei ole tõestatud.
English: 7 tablets 10 tablets 28 tablets 30 tablets 100 tablets 112 tablets
Estonian: 7 tabletti 10 tabletti 28 tabletti 30 tabletti 100 tabletti 112 tabletti
English: What you need to know before you take AZILECT Do not take AZILECT
Estonian: Mida on vaja teada enne AZILECT'i võtmist Ärge võtke AZILECT'i:
English: Very common (may affect more than 1 in 10 people) - Involuntary movements (dyskinesia) - Headache
Estonian: Väga sage (võib esineda rohkem kui 1 inimesel 10-st) - tahtmatud liigutused (düskineesia) - peavalu
English: Contents of the pack and other information What AZILECT contains
Estonian: Pakendi sisu ja muu teave Mida AZILECT sisaldab
English: There is no relevant use of AZILECT in children and adolescents.
Estonian: Puudub AZILECT'i asjakohane kasutus lastel ja noorukitel.
English: This might be enhanced if you take other medicines to treat the symptoms of your Parkinson's disease, or if you take medicines which can make you feel drowsy, or if you drink alcohol while taking AZILECT.
Estonian: See võib võimenduda, kui võtate Parkinsoni tõve sümptomite ravimiseks muid ravimeid või võtate ravimeid, mis teevad teid uniseks või kui te tarbite AZILECT'i võtmise aja alkoholi.
English: Adverse reactions are listed below in Tables 1 and 2 by system organ class and frequency using the following conventions: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
Estonian: Kõrvaltoimed on loetletud allpool tabelites 1 ja 2 organsüsteemi klassi ja esinemissageduse konventsiooni kohaselt järgmiselt: väga sage (≥ 1/10), sage (≥ 1/100 kuni < 1/10), aeg-ajalt (≥ 1/1000 kuni < 1/100), harv (≥ 1/10 000 kuni < 1/1000), väga harv (< 1/10 000), teadmata (ei saa hinnata olemasolevate andmete alusel).
English: What AZILECT looks like and contents of the pack
Estonian: Kuidas AZILECT välja näeb ja pakendi sisu
English: MAO Inhibitors
Estonian: MAO inhibiitorid
English: AZILECT contains the active substance rasagiline and it is used for the treatment of Parkinson's disease in adults.
Estonian: AZILECT sisaldab toimeainet rasagiliini ja seda kasutatakse Parkinsoni tõve raviks täiskasvanutel.
English: If you forget to take AZILECT
Estonian: Kui te unustate AZILECT'i võtta
English: Levodopa and other Parkinson's disease medicinal products
Estonian: Levodopa ja muud Parkinsoni tõve ravimpreparaadid
English: The recommended dose of AZILECT is 1 tablet of 1 mg taken by mouth once daily.
Estonian: AZILECT'i soovitatav annus on üks 1 mg tablett suu kaudu üks kord ööpäevas.
English: The metabolism of rasagiline proceeds through two main pathways: N-dealkylation and/or hydroxylation to yield: 1-aminoindan, 3-hydroxy-N-propargyl-1 aminoindan and 3-hydroxy-1-aminoindan.
Estonian: Rasagiliini metabolism kulgeb kahel peamisel teel: N-dealküleerimine ja/või hüdroksüleerimine, mille tulemuseks on 1-aminoindaan, 3-hüdroksü-N-propargüül-1-aminoindaan ja 3-hüdroksü-1-aminoindaan.
English: If you stop taking AZILECT
Estonian: Kui te lõpetate AZILECT'i võtmise
English: AZILECT 1 mg tablets
Estonian: AZILECT 1 mg tabletid
English: The recommended dose of rasagiline is 1 mg (one tablet of AZILECT) once daily, to be taken with or without levodopa.
Estonian: Rasagiliini soovitatav annus on 1 mg (üks AZILECT'i tablett) üks kord ööpäevas, mida võetakse koos levodopaga või ilma.
English: The tablets are available in blister packs of 7, 10, 28, 30, 100 and 112 tablets or in a bottle containing 30 tablets.
Estonian: Tabletid on saadaval blisterpakendites 7, 10, 28, 30, 100 ja 112 tableti kaupa või pudelites, mis sisaldavad 30 tabletti.
English: If you take more AZILECT than you should
Estonian: Kui te võtate AZILECT'i rohkem kui ette nähtud
English: - If you are allergic to rasagiline or any of the other ingredients of this medicine (listed in section 6).
Estonian: - kui olete rasagiliini või selle ravimi mis tahes koostisosade (loetletud lõigus 6) suhtes allergiline; - kui teil on tõsised maksaprobleemid.
English: AZILECT may cause drowsiness and may cause you to suddenly fall asleep during day time activities, especially if you are taking other dopaminergic medicinal products (used for the treatment of Parkinson's disease).
Estonian: AZILECT võib põhjustada uimasust ja ootamatut uinumist päevaste tegevuste ajal, eriti kui võtate muid dopaminergilisi ravimeid (kasutatakse Parkinsoni tõve ravimiseks).
English: The use of AZILECT together with the antidepressants containing fluoxetine or fluvoxamine should be avoided.
Estonian: Tuleb vältida AZILECT'i samaaegset kasutamist koos fluoksetiini või fluvoksamiini sisaldavate antidepressantidega.
English: Elderly No change in dose is required for elderly patients (see section 5.2).
Estonian: Eakad patsiendid Eakatel patsientidel ei ole vaja annust muuta (vt lõik 5.2).